Abstract
Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of α-glutathione S-transferase (α-GST). We also investigated whether α-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and α-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
Keywords: Alkaline Phosphatase (AP), Chronic Liver Disease, Helicobacter pylori, Glutathione S-transferase immunoassay, Liver Function Tests
Current Drug Safety
Title: Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment
Volume: 2 Issue: 1
Author(s): Bensu Karahalil, Seyhan Yagar and Yasemin Ozin
Affiliation:
Keywords: Alkaline Phosphatase (AP), Chronic Liver Disease, Helicobacter pylori, Glutathione S-transferase immunoassay, Liver Function Tests
Abstract: Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of α-glutathione S-transferase (α-GST). We also investigated whether α-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and α-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
Export Options
About this article
Cite this article as:
Karahalil Bensu, Yagar Seyhan and Ozin Yasemin, Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment, Current Drug Safety 2007; 2 (1) . https://dx.doi.org/10.2174/157488607779315426
DOI https://dx.doi.org/10.2174/157488607779315426 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brief Review of Polymorphic Drug-Metabolizing Enzymes in Japanese Populations: Development of a Higher-Throughput Genotyping Method and Proposed Applications
Drug Metabolism Letters The Immunohistochemical Assessment of HPV Related Adenocarcinoma: Pathologic and Clinical Prognostic Significance
Current Pharmaceutical Design FAK and Nanog Cross Talk with p53 in Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach
Current Vascular Pharmacology New Developments in Antimicrobial Use in Sepsis
Current Pharmaceutical Design An Environmentally-Benign Synthesis of Spiro-benzo[1,4]diazepines Using Multi Phase Nano-titania as a Highly Efficient Catalyst via MAOS Technique
Current Organic Synthesis New Therapeutic Platforms for the Treatment of Epithelial and Cutaneous Lesions
Current Drug Delivery Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Environmental Factors and Hypertension
Current Pharmaceutical Design Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design Novel Antimicrobial Agents for the Management of Maxillofacial and Neck Infections
Recent Patents on Anti-Infective Drug Discovery Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Epidemiology and Natural History of Patients with NAFLD
Current Pharmaceutical Design Stable Synthetic Bacteriochlorins: Potent Light-Activated Anti-Cancer Drugs
Current Organic Chemistry Single Molecule Studies in Chemical Biology and Nanosciences
Current Chemical Biology Finding Appropriate Signal Peptides for Secretory Production of Recombinant Glucarpidase: An <i>In Silico</i> Method
Recent Patents on Biotechnology β -Glucans and their Applications in Cancer Therapy: Focus on human studies
Anti-Cancer Agents in Medicinal Chemistry Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design